ATAI logo

Atai Life Sciences NV (ATAI) Company Overview

Profile

Full Name:

Atai Life Sciences N.V.

Sector:

Healthcare

Industry:

Biotechnology

Country:

Germany

IPO:

June 18, 2021

Indexes:

Not included

Description:

ATAI Life Sciences NV is a biotechnology company focused on developing innovative treatments for mental health disorders. They work on new therapies using psychedelics and other compounds to improve patient outcomes. Their goal is to transform mental health care through scientific research and collaboration.

Key Details

Price

$1.80

Annual Revenue

$314.00 K(+34.76% YoY)

Annual EPS

-$0.25(+74.49% YoY)

Annual ROE

-15.77%

Beta

1.66

Events Calendar

Earnings

Next earnings date:

May 15, 2025

Recent quarterly earnings:

Nov 13, 2024

Recent annual earnings:

Mar 24, 2023
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Feb 13, 25 HC Wainwright & Co.
Buy
Nov 18, 24 HC Wainwright & Co.
Buy
Nov 18, 24 Canaccord Genuity
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

FAQ

  • What is the ticker symbol for Atai Life Sciences NV?
  • Does Atai Life Sciences NV pay dividends?
  • What sector is Atai Life Sciences NV in?
  • What industry is Atai Life Sciences NV in?
  • What country is Atai Life Sciences NV based in?
  • When did Atai Life Sciences NV go public?
  • Is Atai Life Sciences NV in the S&P 500?
  • Is Atai Life Sciences NV in the NASDAQ 100?
  • Is Atai Life Sciences NV in the Dow Jones?
  • When was Atai Life Sciences NV's last earnings report?
  • When does Atai Life Sciences NV report earnings?
  • Should I buy Atai Life Sciences NV stock now?

What is the ticker symbol for Atai Life Sciences NV?

The ticker symbol for Atai Life Sciences NV is NASDAQ:ATAI

Does Atai Life Sciences NV pay dividends?

No, Atai Life Sciences NV does not pay dividends

What sector is Atai Life Sciences NV in?

Atai Life Sciences NV is in the Healthcare sector

What industry is Atai Life Sciences NV in?

Atai Life Sciences NV is in the Biotechnology industry

What country is Atai Life Sciences NV based in?

Atai Life Sciences NV is headquartered in Germany

When did Atai Life Sciences NV go public?

Atai Life Sciences NV's initial public offering (IPO) was on June 18, 2021

Is Atai Life Sciences NV in the S&P 500?

No, Atai Life Sciences NV is not included in the S&P 500 index

Is Atai Life Sciences NV in the NASDAQ 100?

No, Atai Life Sciences NV is not included in the NASDAQ 100 index

Is Atai Life Sciences NV in the Dow Jones?

No, Atai Life Sciences NV is not included in the Dow Jones index

When was Atai Life Sciences NV's last earnings report?

Atai Life Sciences NV's most recent earnings report was on Nov 13, 2024

When does Atai Life Sciences NV report earnings?

The next expected earnings date for Atai Life Sciences NV is May 15, 2025

Should I buy Atai Life Sciences NV stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions